BioPharm America™ Digital is a partnering conference where life science leaders partner to drive the future of drug development. Now in its 14th year, the event will be held virtually taking place September 20-23, 2021 as part of Biotech Week Boston.
BioPharm America Digital creates a robust exchange among executives from major pharmaceutical companies, biotechnology companies of every size and stage, investors, and academic institutions. It brings dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. In the virtual format, half of the audience is from outside of the United States.
The event is delivered on partneringONE®, the industry's most robust software platform. Delegates can request and schedule meetings tailored to their strategic business goals to create a dynamic personalized agenda that includes regular alerts for further meeting opportunities. Each scheduled meeting has its own Zoom link provided by EBD Group and delegates worldwide can meet during a four-day, 24-hour schedule to accommodate global time zones.
Attendees can access sessions, company presentations and networking all on the partneringONE® platform. The program focuses on innovation, partnering, and investing with over 30 sessions, including the AI for Drug Development track, presentations from emerging companies, plus access to Biotech Week Boston programs like INCLUSION and the Biotech Week Boston Awards.
BioPharm America is the only event in North America based on the same reputable formula as EBD Group's acclaimed European events BIO-Europe® and BIO-Europe Spring®. For more information and online registration please visit our conference website at https://informaconnect.com/biopharm-america/
Date and Time: On Monday September 20, 2021 at 7:00 am (ends Thursday September 23, 2021 at 5:00 pm)
General Registration: USD 995.00,
Super-early Bird Pricing - Until July 5: USD 795.00,
Early-bird Pricing - Until July 23: USD 895.00
Speakers: Uli Stilz, VP, Novo Nordisk Bio Innovation Hub, John Vandermosten, Senior Biotechnology Analyst, Zacks Investment Research, Stephen Ruhmel, Associate Director, Janssen Clinical Innovation, Johnson and Johnson, USA, Shara Avis Pecoraro, Manager, Strategic Industry Ventures at MD Anderson Cancer Center, Amy Nicole Nayar, VP US Patient Advocacy and Government Affairs, Novartis Gene Therapies, Craig Martin, CEO, Global Genes, Jan Garfinkle, Founder and Managing Partner, Arboretum Ventures, Emily Blynn, Innovation Advisor, USAID